Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10745152 | Parkinsonism & Related Disorders | 2014 | 6 Pages |
Abstract
Our data suggest that trimethobenzamide helps reduce nausea/vomiting during the first 8 weeks of apomorphine therapy, but is generally not needed thereafter. Trimethobenzamide did not worsen parkinsonism nor affect “on” response after apomorphine injection.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Robert A. Hauser, Stuart Isaacson, Thomas Clinch, The Tigan/Apokyn Study Investigators The Tigan/Apokyn Study Investigators,